<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liver transplantation for alcohol-associated liver disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liver transplantation for alcohol-associated liver disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Liver transplantation for alcohol-associated liver disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott L Friedman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Brown, Jr, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Historically, physicians were reluctant to offer liver transplantation to patients with alcohol-associated liver disease. However, in appropriately selected patients, it is clear that transplantation offers an excellent survival advantage similar to that for other disease indications. Prior reluctance stemmed from the perception that the disease was self-inflicted and from concern regarding the risk of alcohol-related damage to sites outside the liver [<a href="#rid1">1,2</a>]. There was also concern that relapse and medication noncompliance would lead to graft failure.</p><p>Alcohol-associated cirrhosis was responsible for 21 percent of all orthotopic liver transplants in 2015 in the United States, according to the Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) report [<a href="#rid3">3</a>]. Liver transplantation appears to be cost-effective for alcohol-associated liver disease, albeit possibly less so than for transplantation for some indications such as primary biliary cholangitis and primary sclerosing cholangitis [<a href="#rid1">1,4,5</a>]. </p><p>The COVID-19 pandemic has led to an increase in both alcohol-associated liver disease as well as a 50 percent increase in waiting list registrations for liver transplantation [<a href="#rid6">6-9</a>]. The underlying reasons are not clear, but could reflect an increase in alcohol use, worsening of liver disease due to COVID-19, and/or increasing awareness and availability of liver transplantation for alcohol-associated liver disease.</p><p>This topic will review liver transplantation for alcohol-associated liver disease. The diagnosis and treatment of alcohol use disorder and the pathogenesis, diagnosis, and treatment of alcohol-associated liver disease are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3613.html" rel="external">"Pathogenesis of alcohol-associated liver disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3611.html" rel="external">"Management of alcohol-associated steatosis and alcohol-associated cirrhosis"</a>.)</p><p></p><p>The allocation of donor livers by the Model for End-stage Liver disease (MELD) is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.)</p><p class="headingAnchor" id="H4110366538"><span class="h1">DEFINING ALCOHOL USE AFTER TRANSPLANTATION</span><span class="headingEndMark"> — </span>While abstinence is the expectation both before and after liver transplantation, there is a range of patterns of alcohol use. Quantification of alcohol consumption after liver transplantation is not standardized, although several terms are used to describe alcohol use:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abstinence </strong>– No alcohol use.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Slips</strong> – Occasional consumption of limited amounts of alcohol with immediate measures to re-establish abstinence [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Harmful and excessive drinking </strong>– Referred to as relapses and defined as more than 40 g alcohol per day; four or more drinks in one day; or drinking for at least four consecutive days [<a href="#rid10">10,11</a>].</p><p></p><p>The Diagnostic and Statistical Manual of Mental Disorders Version V (DSM-5) criteria for the diagnosis of alcohol use disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment", section on 'Diagnosis'</a>.)</p><p>A key consideration in the psychosocial assessment of liver transplant candidates with alcohol-associated liver disease is the level of patients' insight into the harmful effects of alcohol and its impact on their health. However, a literature review indicated that the definition of insight has not been standardized [<a href="#rid12">12</a>]. This issue requires further clarification and alignment among liver transplantation programs.</p><p class="headingAnchor" id="H2833787062"><span class="h1">PRE-TRANSPLANT MANAGEMENT</span></p><p class="headingAnchor" id="H2724861533"><span class="h2">Timing of referral</span><span class="headingEndMark"> — </span>Early referral for transplantation is an important determinant of success, and we recommend that patients with alcohol-associated liver disease who are transplant candidates are referred for transplantation evaluation. With progressively longer waiting times until a suitable donor liver is available, delayed referral may prevent the patient from surviving the evaluation and waiting period [<a href="#rid13">13,14</a>].</p><p>The presence of cirrhosis alone is not sufficient to warrant transplantation. Transplantation is generally considered when a patient has suffered either a complication of portal hypertension or a manifestation of compromised hepatic function. The indications for liver transplantation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation", section on 'Indications'</a>.)</p><p>Early referral for liver transplantation is not always accomplished, in part because of active drinking or a perception among referring clinicians that liver transplantation is not a viable option. However, it is unclear how often patients who are transplant candidates are not being referred for evaluation [<a href="#rid1">1</a>]. In a study of nearly 200 potential liver transplantation candidates according to the American Association for the study of Liver Diseases (AASLD) guidelines, patients with alcohol-associated liver disease were less likely to receive counseling regarding liver transplantation compared with patients with cirrhosis of another etiology (OR 0.10, 95% CI 0.02-0.57) [<a href="#rid15">15</a>]. In this cohort, 41 patients with cirrhosis (21 percent) were referred for transplant evaluation and the most common reason for not referring patients was active alcohol use. </p><p class="headingAnchor" id="H427470577"><span class="h2">Overall risk of alcohol relapse</span><span class="headingEndMark"> — </span>In appropriately selected patients, the alcohol relapse rate after transplantation generally ranges from 10 to 30 percent [<a href="#rid16">16-22</a>]. In two studies of over 600 patients, 5 percent of patients resumed excessive drinking [<a href="#rid23">23,24</a>]. However, there are conflicting data on whether such patients can be identified with accuracy in advance. </p><p>Two groups have proposed multivariate models to better predict alcohol relapse after transplant, incorporating readily definable behaviors and psychosocial factors [<a href="#rid11">11,25</a>]. Further studies are needed to establish their validity.</p><p class="headingAnchor" id="H459691248"><span class="h3">Risk factors for alcohol relapse</span><span class="headingEndMark"> — </span>There are several patient-related factors that affect the likelihood that alcohol use will be resumed following transplantation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Social factors</strong> – Lack of social support is a risk factor for alcohol relapse [<a href="#rid17">17,18,25,26</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychiatric disorder</strong> – Current or previous psychiatric illness is a risk factor for alcohol relapse after liver transplantation; assessment for comorbid psychiatric condition may help identify at-risk patients [<a href="#rid11">11,25-27</a>]. </p><p></p><p class="bulletIndent1">In a study of 387 patients who underwent liver transplantation for alcohol-associated liver disease, patients with psychiatric illness (ie, anxiety or depressive disorder) were more likely to resume harmful alcohol use (ie, &gt;40 g per day) after transplantation (OR 7.8, 95% CI 3.1-20) [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history of alcohol dependence</strong> – Family history of alcohol dependence correlated with risk of alcohol relapse in one meta-analysis, but the strength of the correlation was modest [<a href="#rid18">18</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noncompliance</strong> – In a study of 195 patients with alcohol-associated liver disease who underwent liver transplantation, noncompliance with office visits after transplantation was a nonsignificant risk factor for alcohol relapse (OR 4.36, 95% 0.92-15.43) [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis C virus infection</strong> – Liver disease due to both alcohol and hepatitis C virus (HCV) infection is not uncommon, but the presence of HCV does not result in greater risk of alcohol relapse following transplantation. In a study of 167 post-transplant patients with a history of either alcohol-associated liver disease alone or HCV and alcohol-associated liver disease, there was no significant difference in alcohol relapse rates (18 versus 8 percent) [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Younger age</strong> – Younger age is not consistently associated with a higher rate of alcohol relapse [<a href="#rid16">16,17,22,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of abstinence pre-transplant</strong> – Longer periods of abstinence pre-transplant appear to be associated with lower risks of alcohol relapse. (See <a class="local">'Pre-transplant abstinence and monitoring'</a> below.)</p><p></p><p>A score incorporating several factors (age at liver transplantation, nonalcohol-related criminal history, pre-transplantation alcohol abstinence, and number of drinks per day) has been developed and has shown promise for identifying patients at increased risk for alcohol relapse [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H599304101"><span class="h2">Pre-transplant abstinence and monitoring</span></p><p class="headingAnchor" id="H2734040102"><span class="h3">Six-month rule</span><span class="headingEndMark"> — </span>Six months of abstinence is still a requirement prior to placement on the transplantation waiting list at many programs for two reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>To identify patients who are at risk for relapse</p><p class="bulletIndent1"><span class="glyph">●</span>To allow time for liver recovery from ongoing alcohol-related injury</p><p></p><p>The six-month rule affects the eligibility of patients with alcohol-associated liver disease for transplantation. Some transplantation programs and society guidelines suggest that no absolute interval of abstinence is required because some patients who are otherwise suitable candidates will not survive a period of six months. (See <a class="local">'Patients with severe alcohol-associated hepatitis (AH)'</a> below.)</p><p>Based on the available studies, it is increasingly less certain that the six-month abstinence requirement significantly reduces the rate of relapse after transplantation or improves outcomes [<a href="#rid11">11,16,25,33-35</a>].<em> </em>While the six-month abstinence requirement is somewhat arbitrary, some [<a href="#rid11">11,33,36</a>] but not all [<a href="#rid16">16,25,34</a>] studies have found that longer duration of abstinence before transplant is associated with lower alcohol relapse rates after transplant. For example, in one study, for every month of pre-transplantation abstinence, there was a 5 percent decrease in the adjusted relapse rate [<a href="#rid36">36</a>]. However, in a cohort study comparing earlier liver transplant (ie, &lt;6 months) with standard transplant (ie, adherence to the six-month rule), there were no significant differences in rates of patient survival, graft survival, and relapse-free survival between groups [<a href="#rid37">37</a>]. </p><p>An additional consideration is that patient-reported alcohol use may not be accurate. In a study of 40 patients with alcohol-associated liver disease who were referred for liver transplant evaluation, urine toxicological screening was positive for any substance in 15 patients (38 percent) and for alcohol in eight patients (20 percent) [<a href="#rid38">38</a>]. However, only 3 percent of the patients admitted to using alcohol. </p><p class="headingAnchor" id="H524604209"><span class="h3">Alcohol treatment program</span><span class="headingEndMark"> — </span>In addition to adhering to the six-month rule, some transplant centers require that patients enroll in a substance abuse treatment program such as Alcoholics Anonymous. In a study of 118 patients who underwent liver transplantation, participation in a substance disorder treatment program both before and after liver transplantation lowered the post-transplant alcohol relapse rate compared with those who only participated in a treatment program before transplant or those who received no treatment (16 percent versus 45 and 41 percent, respectively) [<a href="#rid39">39</a>]. </p><p class="headingAnchor" id="H1813749101"><span class="h3">Monitoring for alcohol use</span><span class="headingEndMark"> — </span>We monitor patients with alcohol-associated liver disease for alcohol use both prior to and following liver transplantation by clinical interview and by testing of urine ethyl glucuronide (EtG) during outpatient visits and randomly, if needed. Urine ethyl glucuronide can be detected for up to 80 hours after complete ethanol elimination from the body and after consumption of less than 5 g of ethanol, and has low false positive rates [<a href="#rid40">40,41</a>]. In one study of 121 patients with alcohol-associated liver disease who were either candidates for or recipients of liver transplantation, alcohol consumption was detected by clinical interview (using a validated screening tool) or by patient response to abnormal tests (ie, urine or blood markers of alcohol use) in 31 percent of patients [<a href="#rid42">42</a>]. Urine ethyl glucuronide was the strongest marker of alcohol consumption (OR 415, 95% CI 51 to &gt;1000), but assessing for ethyl glucuronide in hair may be a simpler alternative [<a href="#rid43">43</a>]. </p><p>Additional methods for monitoring patients for alcohol use include assessment of blood or breathalyzer alcohol levels [<a href="#rid44">44-46</a>]. The available data suggest that the serum marker phosphatidylethanol is more sensitive for detecting chronic alcohol use compared with other blood tests (eg, carbohydrate deficient transferrin) [<a href="#rid47">47,48</a>].</p><p>Some centers randomly check blood alcohol levels in patients on the transplant waiting list. In a study of 134 such patients in whom alcohol use was defined as a positive blood alcohol level, self-reported alcohol use or refusal to check a blood alcohol level within 12 hours of the request, alcohol use was less likely in patients with a higher number of random blood alcohol level checks (RR 0.63, 95% CI 0.52-0.76) and with a longer duration of prelisting abstinence (RR 0.88, 95% 0.83-0.94) [<a href="#rid49">49</a>]. This study did not address whether this practice reduced post-transplant alcohol relapse.</p><p>Carbohydrate deficient transferrin is a laboratory test that is elevated in the setting of sustained heavy alcohol use (ie, six standard drinks for two weeks or more), but it can also be elevated in patients with advanced liver disease who are abstinent. Thus, carbohydrate deficient transferrin levels should be interpreted with caution. (See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment", section on 'Laboratory evaluation'</a>.)</p><p class="headingAnchor" id="H828336315"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>Smoking remains an independent and significant risk factor for post-transplant morbidity and mortality [<a href="#rid50">50,51</a>]. Long-term follow-up of patients who have undergone liver transplantation for alcohol-associated liver disease has shown an increased rate of lung, liver, and oropharyngeal cancer compared to patients transplanted for other indications [<a href="#rid52">52,53</a>]. It is likely that this association is due to the relatively high prevalence of smoking in this population combined with the impact of immunosuppression on tumor surveillance. Moreover, long-term morbidity and mortality are also linked to continued smoking, which accelerates cardiovascular and cancer risk [<a href="#rid1">1</a>]. </p><p>Increasing emphasis or insistence on enrollment of patients into smoking cessation programs has been advocated to reduce morbidity post-transplantation [<a href="#rid54">54,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>Some authorities have advocated removing patients from the transplant waiting list who continue to smoke despite these interventions. Roughly 20 percent of transplant centers report that they will refuse to list patients due to smoking [<a href="#rid56">56</a>]. One report found that up to 40 percent of patients who had undergone transplantation for alcohol-associated liver disease resumed smoking early in the post-transplant course, underscoring the need for continued counseling and monitoring after transplantation [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H831262080"><span class="h2">Other goals of pre-transplant evaluation</span><span class="headingEndMark"> — </span>The goal of the pre-transplantation evaluation is to assess the patient's ability to tolerate the stress of surgery, immunosuppression, and the demands of post-transplantation care. The details of the extensive cardiopulmonary, psychosocial and screening evaluation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation", section on 'Pretransplantation evaluation'</a>.)</p><p class="headingAnchor" id="H4238569736"><span class="h1">PATIENTS WITH SEVERE ALCOHOL-ASSOCIATED HEPATITIS (AH)</span><span class="headingEndMark"> — </span>Liver transplantation may be the only treatment option for patients with severe AH who do not respond to glucocorticoids, and transplantation has been lifesaving for some patients [<a href="#rid58">58-60</a>]. The number of patients undergoing liver transplantation for acute AH has been steadily increasing in the United States, with marked geographic variation because a limited number of centers perform transplantation for this indication [<a href="#rid8">8,58,61,62</a>]. Patients who are transplanted for AH are generally younger, have higher MELD scores, and are more frequently on renal dialysis compared with patients transplanted for other indications [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/87052.html" rel="external">"Management and prognosis of alcoholic hepatitis", section on 'Liver transplantation'</a>.)</p><p>It has been suggested that the six-month period of abstinence be reconsidered in patients with severe AH and that methods to identify risk factors for alcohol relapse are needed [<a href="#rid63">63</a>]. While recurrent harmful alcohol use is associated with post-transplant morbidity, the risk for alcohol relapse is not well defined and may be similar to patients who complete a six-month period of abstinence prior to transplantation [<a href="#rid64">64</a>].</p><p>At most transplant centers, criteria for selecting patients with AH require that there is no prior history of liver decompensation because prior decompensation has been associated with higher risk of mortality and alcohol relapse [<a href="#rid65">65,66</a>]. In a study including 241 patients who underwent liver transplantation for severe AH, patients with a prior history of decompensation had higher risk of mortality and harmful alcohol use after transplantation compared with no prior decompensation (adjusted hazard ratio [aHR] 2.72, 95% CI 1.61-4.59 and aHR 1.77, 95% CI 1.07-2.94, respectively) [<a href="#rid66">66</a>]. However, rates of overall survival at one and three years among patients with prior decompensation were good (86 and 78 percent, respectively). Criteria for patient selection remain highly variable among centers, and additional studies with long-term follow-up are needed to optimize criteria for liver transplantation. </p><p>In general, patients who have AH are infrequently transplanted because the diagnosis of AH implies recent harmful alcohol use and because some patients will improve without transplantation. In principle, the chronic inflammatory state associated with AH has the potential to increase perioperative complications, although most studies found that long-term morbidity is related primarily to recurrent alcohol use disorder rather than acute complications of transplantation [<a href="#rid5">5,11,17,67</a>]. (See  <a class="medical medical_review" href="/z/d/html/86934.html" rel="external">"Alcoholic hepatitis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">POST-TRANSPLANT OUTCOMES</span></p><p class="headingAnchor" id="H1012494760"><span class="h2">Management</span><span class="headingEndMark"> — </span>The general management of patients following liver transplantation including the approach to immunosuppression and its complications, preventative medicine, and diagnosis and treatment of acute cellular rejection are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">"Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4598.html" rel="external">"Liver transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection of the liver allograft"</a>.)</p><p></p><p class="headingAnchor" id="H3729699156"><span class="h2">Mortality and graft survival</span><span class="headingEndMark"> — </span>Short term patient and graft survival rates following liver transplantation for alcohol-associated liver disease are similar to rates following transplantation for nonalcohol-related diagnoses; however, the 10-year patient and graft survival rates are lower for patients with alcohol-associated liver disease [<a href="#rid68">68-71</a>]. In a cohort study of the United Network of Organ Sharing database including 9438 patients with alcohol-associated liver disease who were transplanted, the following outcomes were reported [<a href="#rid71">71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient survival</strong> – Patient survival rates at one year and at five years were similar for patients with alcohol-associated liver disease compared with patients with nonalcohol-associated disease (one year: 91 versus 90 percent; five years: 79 versus 80 percent). However, patient survival rates at 10 years were lower for patients with alcohol-associated liver disease compared with those with a nonalcohol-related diagnosis (63 versus 68 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft survival</strong> – Graft survival rates at one and at five years were similar for patients with alcohol-associated liver disease compared with patients with nonalcohol-associated disease (one year: 91 versus 89 percent; five years: 79 versus 80 percent). However, graft survival rates at 10 years were lower for patients with alcohol-associated liver disease compared with those with a nonalcohol-related diagnosis (60 versus 63 percent). </p><p></p><p>The increase in mortality at 10 years after liver transplant in patients with alcohol-associated liver disease suggests the need for long-term follow-up studies to identify risk factors for mortality, so that patient selection for transplantation and post-transplant care can be optimized for long-term survival [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients"</a>.) </p><p class="headingAnchor" id="H963614413"><span class="h2">Recurrent harmful alcohol use</span><span class="headingEndMark"> — </span>Despite comprehensive pre-transplant evaluation and adherence to the six-month rule by most centers, some patients will resume alcohol use following liver transplantation. (See <a class="local">'Overall risk of alcohol relapse'</a> above.)</p><p>A model has been developed to identify individuals who drink heavily and are at high risk for liver disease progression that incorporates patient sex, baseline fibrosis levels, onset of heavy drinking, amount of alcohol intake, and body mass index [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H3074843652"><span class="h3">Complications</span><span class="headingEndMark"> — </span>Graft rejection, graft loss and recurrent alcohol-associated liver disease are potential complications of alcohol relapse after liver transplantation [<a href="#rid27">27</a>]. Excessive drinking after liver transplantation may be associated with rapidly progressive liver injury, allograft failure, and fatal alcohol-associated hepatitis (AH) [<a href="#rid24">24,73-75</a>]. In a study of 300 patients with alcohol-associated liver disease who underwent transplantation, patients who relapsed were more likely to develop steatohepatitis (OR 6.2, 95% CI 1.7-22.7) and advanced (stage three or higher) fibrosis (OR 23.2, 95% CI 3.1-177.3) compared with those who maintained abstinence [<a href="#rid24">24</a>]. In another study, 128 of 712 patients who underwent liver transplantation for alcohol-associated cirrhosis had a severe alcohol relapse [<a href="#rid21">21</a>]. Among the patients with a severe relapse, 41 (32 percent) developed recurrent alcohol-associated cirrhosis after a median of 5.1 years. Survival at 10 and 15 years was lower among patients with severe alcohol relapse compared with those who did not have a severe relapse (50 versus 70 percent at 10 years and 21 versus 41 percent at 15 years). A separate report also suggested impaired survival after 10 years in patients who resumed drinking, possibly because of an increased risk of death from cancer and cardiovascular events [<a href="#rid76">76</a>]. However, in one study, alcohol use in the immediate pre-transplant period was not associated with lower long-term survival [<a href="#rid77">77</a>].</p><p>The continued use of alcohol by patients after liver transplantation may also increase the likelihood that they will be lost to follow-up, leading to an underestimate of the impact of alcohol use on outcomes.</p><p class="headingAnchor" id="H448290166"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>We monitor patients with a history of alcohol-associated liver disease for recurrent alcohol use following liver transplantation by clinical interview and by testing of urine ethyl glucuronide (uEtG) at each follow-up outpatient visit and randomly, if needed. (See <a class="local">'Monitoring for alcohol use'</a> above.)</p><p class="headingAnchor" id="H10"><span class="h3">Prevention and treatment</span><span class="headingEndMark"> — </span>Patients with either alcohol-associated liver disease who did not complete an alcohol treatment program prior to liver transplantation or with acute severe AH are required to sign a patient contract prior to transplantation. They also must complete an alcohol treatment program when medically appropriate following transplantation (usually three to six months postoperatively). </p><p>Few studies have addressed the utility of post-liver transplantation alcohol treatment programs in preventing relapse. In a study of 103 patients with alcohol-associated liver disease who underwent transplantation, participation in an alcohol treatment program resulted in lower rates of any alcohol use during a four-year follow-up period (22 versus 48 percent) [<a href="#rid22">22</a>]. In the United Kingdom, all patients who undergo transplantation for alcohol-associated liver disease are followed by an addiction treatment psychiatrist [<a href="#rid78">78,79</a>]. Such a program is recommended but not mandatory in the United States. </p><p>Psychosocial and pharmacologic treatment of alcohol use disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">"Alcohol use disorder: Psychosocial management"</a>.)</p><p class="headingAnchor" id="H83729186"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113977.html" rel="external">"Society guideline links: Liver transplantation"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Alcohol-associated cirrhosis was responsible for 21 percent of all orthotopic liver transplants in 2015 in the United States, according to the Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) report. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Transplantation is an appropriate treatment option for some patients with alcohol-associated liver disease and is generally considered when a patient has suffered either a complication of portal hypertension or a manifestation of compromised hepatic function. Such patients should be referred for transplantation as early referral is an important determinant of success. (See <a class="local">'Timing of referral'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-transplant abstinence and monitoring</strong> – Abstinence is an expectation for patients on the transplant waiting list. Some studies suggest that longer durations of abstinence pre-transplantation are associated with reduced rates of relapse after transplant; six-month abstinence is a common requirement in many centers. In addition, other centers monitor patients for alcohol use and/or require that patients participate in an alcohol treatment program. The efficacy of these measures in preventing alcohol relapse after transplantation and improving other outcomes is uncertain.<em> </em>(See <a class="local">'Pre-transplant abstinence and monitoring'</a> above.)<em> </em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-transplant management and outcomes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mortality and graft survival – One- and five-year patient and graft survival rates following liver transplantation for alcohol-associated liver disease are similar to rates following transplantation for nonalcohol-related diagnoses. However, 10-year patient and graft survival rates are lower for patients with alcohol-associated liver disease, while the cause for this is not well-defined. (See <a class="local">'Mortality and graft survival'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent harmful alcohol use – Alcohol relapse after transplantation occurs in 10 to 30 percent of patients and has been associated with increased risk of graft rejection, graft loss, and recurrent alcohol-associated liver disease as well as decreased survival. The accuracy of predictors of relapse is incompletely understood but, poor social support, a family history of alcohol dependence, and pre-transplantation abstinence of ≤6 months are some of the predictors that may be important. (See <a class="local">'Risk factors for alcohol relapse'</a> above and <a class="local">'Recurrent harmful alcohol use'</a> above.)</p><p></p><p class="bulletIndent2">We suggest that patients with a history of alcohol-associated liver disease participate in an alcohol treatment program following liver transplantation. (See <a class="local">'Prevention and treatment'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Smoking cessation – Smoking is a significant risk factor for post-transplant morbidity and mortality. We suggest that patients with alcohol-associated liver disease who smoke undergo counseling and treatment for smoking cessation (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Smoking cessation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with severe alcohol-associated hepatitis (AH)</strong> – Liver transplantation may be an option for patients with severe AH who do not respond to glucocorticoids. It has been suggested that the six-month period of abstinence be reconsidered in patients with severe AH and that methods to identify transplant candidates who are at low risk of relapse are needed. (See <a class="local">'Patients with severe alcohol-associated hepatitis (AH)'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl 2011; 17:751.</a></li><li><a class="nounderline abstract_t">Cohen C, Benjamin M. Alcoholics and liver transplantation. The Ethics and Social Impact Committee of the Transplant and Health Policy Center. JAMA 1991; 265:1299.</a></li><li><a class="nounderline abstract_t">Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 Annual Data Report: Liver. Am J Transplant 2017; 17 Suppl 1:174.</a></li><li><a class="nounderline abstract_t">Longworth L, Young T, Buxton MJ, et al. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 2003; 9:1295.</a></li><li><a class="nounderline abstract_t">O'Grady JG. Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet's nest! Gut 2006; 55:1529.</a></li><li><a class="nounderline abstract_t">Sohal A, Khalid S, Green V, et al. The Pandemic Within the Pandemic: Unprecedented Rise in Alcohol-related Hepatitis During the COVID-19 Pandemic. J Clin Gastroenterol 2022; 56:e171.</a></li><li><a class="nounderline abstract_t">Anderson MS, Valbuena VSM, Brown CS, et al. Association of COVID-19 With New Waiting List Registrations and Liver Transplantation for Alcoholic Hepatitis in the United States. JAMA Netw Open 2021; 4:e2131132.</a></li><li><a class="nounderline abstract_t">Bittermann T, Mahmud N, Abt P. Trends in Liver Transplantation for Acute Alcohol-Associated Hepatitis During the COVID-19 Pandemic in the US. JAMA Netw Open 2021; 4:e2118713.</a></li><li><a class="nounderline abstract_t">Kuo YF, Kwo P, Wong RJ, Singal AK. Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications. J Clin Transl Hepatol 2023; 11:130.</a></li><li><a class="nounderline abstract_t">Lucey MR. Liver transplantation for alcoholic liver disease: past, present, and future. Liver Transpl 2007; 13:190.</a></li><li><a class="nounderline abstract_t">De Gottardi A, Spahr L, Gelez P, et al. A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. Arch Intern Med 2007; 167:1183.</a></li><li><a class="nounderline abstract_t">Winder GS, Clifton EG, Fernandez AC, et al. Definition and measurement of alcohol-associated insight in early liver transplantation for acute alcohol-associated hepatitis: A systematic review. Liver Transpl 2023; 29:757.</a></li><li><a class="nounderline abstract_t">Watt KD, McCashland TM. Transplantation in the alcoholic patient. Semin Liver Dis 2004; 24:249.</a></li><li class="breakAll">https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/# (Accessed on August 16, 2017).</li><li><a class="nounderline abstract_t">Julapalli VR, Kramer JR, El-Serag HB, American Association for the Study of Liver Diseases. Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. Liver Transpl 2005; 11:1370.</a></li><li><a class="nounderline abstract_t">Jauhar S, Talwalkar JA, Schneekloth T, et al. Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl 2004; 10:408.</a></li><li><a class="nounderline abstract_t">Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2007; 13:197.</a></li><li><a class="nounderline abstract_t">Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008; 14:159.</a></li><li><a class="nounderline abstract_t">Miguet M, Monnet E, Vanlemmens C, et al. Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease. Gastroenterol Clin Biol 2004; 28:845.</a></li><li><a class="nounderline abstract_t">McCallum S, Masterton G. Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. Alcohol Alcohol 2006; 41:358.</a></li><li><a class="nounderline abstract_t">Dumortier J, Dharancy S, Cannesson A, et al. Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication. Am J Gastroenterol 2015; 110:1160.</a></li><li><a class="nounderline abstract_t">Björnsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol 2005; 40:206.</a></li><li><a class="nounderline abstract_t">Schmeding M, Heidenhain C, Neuhaus R, et al. Liver transplantation for alcohol-related cirrhosis: a single centre long-term clinical and histological follow-up. Dig Dis Sci 2011; 56:236.</a></li><li><a class="nounderline abstract_t">Rice JP, Eickhoff J, Agni R, et al. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl 2013; 19:1377.</a></li><li><a class="nounderline abstract_t">Kelly M, Chick J, Gribble R, et al. Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol 2006; 41:278.</a></li><li><a class="nounderline abstract_t">DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 2006; 12:813.</a></li><li><a class="nounderline abstract_t">Lim J, Curry MP, Sundaram V. Risk factors and outcomes associated with alcohol relapse after liver transplantation. World J Hepatol 2017; 9:771.</a></li><li><a class="nounderline abstract_t">Egawa H, Nishimura K, Teramukai S, et al. Risk factors for alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan. Liver Transpl 2014; 20:298.</a></li><li><a class="nounderline abstract_t">Deutsch-Link S, Weinrieb RM, Jones LS, et al. Prior Relapse, Ongoing Alcohol Consumption, and Failure to Engage in Treatment Predict Alcohol Relapse After Liver Transplantation. Dig Dis Sci 2020; 65:2089.</a></li><li><a class="nounderline abstract_t">Aguilera V, Berenguer M, Rubín A, et al. Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. Liver Transpl 2009; 15:79.</a></li><li><a class="nounderline abstract_t">Grąt M, Lewandowski Z, Grąt K, et al. Negative outcomes after liver transplantation in patients with alcoholic liver disease beyond the fifth post-transplant year. Clin Transplant 2014; 28:1112.</a></li><li><a class="nounderline abstract_t">Satapathy SK, Thornburgh C, Heda R, et al. Predicting harmful alcohol relapse after liver transplant: The HALT score. Clin Transplant 2020; 34:e14003.</a></li><li><a class="nounderline abstract_t">Karim Z, Intaraprasong P, Scudamore CH, et al. Predictors of relapse to significant alcohol drinking after liver transplantation. Can J Gastroenterol 2010; 24:245.</a></li><li><a class="nounderline abstract_t">Perney P, Bismuth M, Sigaud H, et al. Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease? Transpl Int 2005; 18:1292.</a></li><li><a class="nounderline abstract_t">Chen PH, Sung HC, Punchhi G, et al. Patient reflections, challenges, and supports related to early liver transplant for severe alcohol-associated liver disease. Liver Transpl 2023; 29:745.</a></li><li><a class="nounderline abstract_t">Tandon P, Goodman KJ, Ma MM, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009; 104:1700.</a></li><li><a class="nounderline abstract_t">Herrick-Reynolds KM, Punchhi G, Greenberg RS, et al. Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease. JAMA Surg 2021; 156:1026.</a></li><li><a class="nounderline abstract_t">Webzell I, Ball D, Bell J, et al. Substance use by liver transplant candidates: an anonymous urinalysis study. Liver Transpl 2011; 17:1200.</a></li><li><a class="nounderline abstract_t">Rodrigue JR, Hanto DW, Curry MP. Substance abuse treatment and its association with relapse to alcohol use after liver transplantation. Liver Transpl 2013; 19:1387.</a></li><li><a class="nounderline abstract_t">Staufer K, Andresen H, Vettorazzi E, et al. Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption. Hepatology 2011; 54:1640.</a></li><li><a class="nounderline abstract_t">Böttcher M, Beck O, Helander A. Evaluation of a new immunoassay for urinary ethyl glucuronide testing. Alcohol Alcohol 2008; 43:46.</a></li><li><a class="nounderline abstract_t">Piano S, Marchioro L, Gola E, et al. Assessment of alcohol consumption in liver transplant candidates and recipients: the best combination of the tools available. Liver Transpl 2014; 20:815.</a></li><li><a class="nounderline abstract_t">Staufer K, Huber-Schönauer U, Strebinger G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol 2022; 77:918.</a></li><li><a class="nounderline abstract_t">Addolorato G, Bataller R, Burra P, et al. Liver Transplantation for Alcoholic Liver Disease. Transplantation 2016; 100:981.</a></li><li><a class="nounderline abstract_t">Viel G, Boscolo-Berto R, Cecchetto G, et al. Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta-analysis. Int J Mol Sci 2012; 13:14788.</a></li><li><a class="nounderline abstract_t">Shen NT, Salajegheh A, Brown RS Jr. A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease. Hepatology 2019; 70:1038.</a></li><li><a class="nounderline abstract_t">Aradottir S, Asanovska G, Gjerss S, et al. PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol 2006; 41:431.</a></li><li><a class="nounderline abstract_t">Hartmann S, Aradottir S, Graf M, et al. Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addict Biol 2007; 12:81.</a></li><li><a class="nounderline abstract_t">Carbonneau M, Jensen LA, Bain VG, et al. Alcohol use while on the liver transplant waiting list: a single-center experience. Liver Transpl 2010; 16:91.</a></li><li><a class="nounderline abstract_t">Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10:1420.</a></li><li><a class="nounderline abstract_t">Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19:3.</a></li><li><a class="nounderline abstract_t">Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7:149.</a></li><li><a class="nounderline abstract_t">Jain A, DiMartini A, Kashyap R, et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70:1335.</a></li><li><a class="nounderline abstract_t">Muñoz SJ. Tobacco use by liver transplant recipients: grappling with a smoking gun. Liver Transpl 2005; 11:606.</a></li><li><a class="nounderline abstract_t">Bataller R. Time to ban smoking in patients with chronic liver diseases. Hepatology 2006; 44:1394.</a></li><li><a class="nounderline abstract_t">Ehlers SL, Rodrigue JR, Widows MR, et al. Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research. Liver Transpl 2004; 10:412.</a></li><li><a class="nounderline abstract_t">DiMartini A, Javed L, Russell S, et al. Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem. Liver Transpl 2005; 11:679.</a></li><li><a class="nounderline abstract_t">Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365:1790.</a></li><li><a class="nounderline abstract_t">Singal AK, Bashar H, Anand BS, et al. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology 2012; 55:1398.</a></li><li><a class="nounderline abstract_t">Im GY, Kim-Schluger L, Shenoy A, et al. Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience. Am J Transplant 2016; 16:841.</a></li><li><a class="nounderline abstract_t">Ayyala-Somayajula D, Han H, Terrault NA. Selective use of liver transplantation for severe alcohol-associated hepatitis. Expert Rev Gastroenterol Hepatol 2020; 14:175.</a></li><li><a class="nounderline abstract_t">Cotter TG, Sandıkçı B, Paul S, et al. Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. Am J Transplant 2021; 21:1039.</a></li><li><a class="nounderline abstract_t">Brown RS Jr. Transplantation for alcoholic hepatitis--time to rethink the 6-month "rule". N Engl J Med 2011; 365:1836.</a></li><li><a class="nounderline abstract_t">Lee BP, Chen PH, Haugen C, et al. Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis. Ann Surg 2017; 265:20.</a></li><li><a class="nounderline abstract_t">Lee BP, Mehta N, Platt L, et al. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology 2018; 155:422.</a></li><li><a class="nounderline abstract_t">Weinberg EM, Dukewich M, Jakhete N, et al. Early Liver Transplantation for Severe Alcohol-Associated Hepatitis and a History of Prior Liver Decompensation. Am J Gastroenterol 2022; 117:1990.</a></li><li><a class="nounderline abstract_t">De Gottardi A, Dumortier J. Transplantation for alcoholic liver disease. Gut 2007; 56:735.</a></li><li><a class="nounderline abstract_t">Bellamy CO, DiMartini AM, Ruppert K, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001; 72:619.</a></li><li><a class="nounderline abstract_t">Young TA, Neuberger J, Longworth L, et al. Survival gain after liver transplantation for patients with alcoholic liver disease: a comparison across models and centers. Transplantation 2003; 76:1479.</a></li><li><a class="nounderline abstract_t">Webb K, Shepherd L, Day E, et al. Transplantation for alcoholic liver disease: report of a consensus meeting. Liver Transpl 2006; 12:301.</a></li><li><a class="nounderline abstract_t">Lee BP, Vittinghoff E, Dodge JL, et al. National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States. JAMA Intern Med 2019; 179:340.</a></li><li><a class="nounderline abstract_t">Delacôte C, Bauvin P, Louvet A, et al. A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression. Clin Gastroenterol Hepatol 2020; 18:2315.</a></li><li><a class="nounderline abstract_t">Conjeevaram HS, Hart J, Lissoos TW, et al. Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. Transplantation 1999; 67:1562.</a></li><li><a class="nounderline abstract_t">Pageaux GP, Bismuth M, Perney P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol 2003; 38:629.</a></li><li><a class="nounderline abstract_t">Erard-Poinsot D, Guillaud O, Hervieu V, et al. Severe alcoholic relapse after liver transplantation: What consequences on the graft? A study based on liver biopsies analysis. Liver Transpl 2016; 22:773.</a></li><li><a class="nounderline abstract_t">Cuadrado A, Fábrega E, Casafont F, Pons-Romero F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2005; 11:420.</a></li><li><a class="nounderline abstract_t">Ursic-Bedoya J, Dumortier J, Altwegg R, et al. Alcohol Consumption the Day of Liver Transplantation for Alcohol-Associated Liver Disease Does Not Affect Long-Term Survival: A Case-Control Study. Liver Transpl 2021; 27:34.</a></li><li><a class="nounderline abstract_t">Bathgate AJ, UK Liver Transplant Units. Recommendations for alcohol-related liver disease. Lancet 2006; 367:2045.</a></li><li><a class="nounderline abstract_t">Kotlyar DS, Burke A, Campbell MS, Weinrieb RM. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103:734.</a></li></ol></div><div id="topicVersionRevision">Topic 3608 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21567894" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Liver transplantation in patients with alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1995978" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Alcoholics and liver transplantation. The Ethics and Social Impact Committee of the Transplant and Health Policy Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052604" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : OPTN/SRTR 2015 Annual Data Report: Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625830" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047102" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet's nest!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34653062" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Pandemic Within the Pandemic: Unprecedented Rise in Alcohol-related Hepatitis During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34698851" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Association of COVID-19 With New Waiting List Registrations and Liver Transplantation for Alcoholic Hepatitis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34323988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends in Liver Transplantation for Acute Alcohol-Associated Hepatitis During the COVID-19 Pandemic in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36406316" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17256778" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Liver transplantation for alcoholic liver disease: past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563028" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37016758" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Definition and measurement of alcohol-associated insight in early liver transplantation for acute alcohol-associated hepatitis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349803" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Transplantation in the alcoholic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349803" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transplantation in the alcoholic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16184521" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004769" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Analysis of factors that predict alcohol relapse following liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205563" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18236389" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15523219" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636009" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169514" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764153" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20499174" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Liver transplantation for alcohol-related cirrhosis: a single centre long-term clinical and histological follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24115392" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476764" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predictors of relapse to harmful alcohol after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16528710" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28660011" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk factors and outcomes associated with alcohol relapse after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24470014" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors for alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31707529" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prior Relapse, Ongoing Alcohol Consumption, and Failure to Engage in Treatment Predict Alcohol Relapse After Liver Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109849" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25059535" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Negative outcomes after liver transplantation in patients with alcoholic liver disease beyond the fifth post-transplant year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32506677" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Predicting harmful alcohol relapse after liver transplant: The HALT score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20431813" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predictors of relapse to significant alcohol drinking after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221161" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36728621" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Patient reflections, challenges, and supports related to early liver transplant for severe alcohol-associated liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19471253" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34379106" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21744466" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Substance use by liver transplant candidates: an anonymous urinalysis study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123780" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Substance abuse treatment and its association with relapse to alcohol use after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21809364" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942435" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evaluation of a new immunoassay for urinary ethyl glucuronide testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24692331" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Assessment of alcohol consumption in liver transplant candidates and recipients: the best combination of the tools available.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35605744" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26985744" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Liver Transplantation for Alcoholic Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23203094" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30802988" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16624837" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407500" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19866447" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Alcohol use while on the liver transplant waiting list: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20486907" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23281277" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455479" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Alcohol and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087149" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915485" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tobacco use by liver transplant recipients: grappling with a smoking gun.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133465" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Time to ban smoking in patients with chronic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004770" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915490" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22070476" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Early liver transplantation for severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22213344" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26710309" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32077333" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Selective use of liver transplantation for severe alcohol-associated hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32531107" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22070481" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Transplantation for alcoholic hepatitis--time to rethink the 6-month "rule".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27280501" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29655837" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35853462" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Early Liver Transplantation for Severe Alcohol-Associated Hepatitis and a History of Prior Liver Decompensation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17148501" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Transplantation for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11544420" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657690" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Survival gain after liver transplantation for patients with alcoholic liver disease: a comparison across models and centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16447187" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Transplantation for alcoholic liver disease: report of a consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30667468" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31931181" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401763" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12713874" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26929100" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Severe alcoholic relapse after liver transplantation: What consequences on the graft? A study based on liver biopsies analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15776421" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32978890" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Alcohol Consumption the Day of Liver Transplantation for Alcohol-Associated Liver Disease Does Not Affect Long-Term Survival: A Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16798373" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Recommendations for alcohol-related liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18081918" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
